| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6493e075b586cf5568b69116429349a8 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7061
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7069
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-27 |
| filingDate |
2016-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f54f9fd6a7ea5b7464da4f3e7c804db8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9fb4064b7e8a2f363ac521dd51817d42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25c9cff758e2cdec838d385c60ce8d12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1fac5f1abcd07ac2a9a0c85665be7b34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_252705d79117c029cea1b1a5f51a869a |
| publicationDate |
2017-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
DK-201600113-Y4 |
| titleOfInvention |
Transdermal therapeutic system for administration of rivastigmine |
| abstract |
The invention relates to rivastigmine as a free base or in the form of a pharmaceutically acceptable salt for use in a method of preventing, treating or delaying the development of dementia or Alzheimer's disease, wherein rivastigmine is administered in a Transdermal Therapeutic System and the starting dose is greater than 3 mg. rivastigmine per day. |
| priorityDate |
2005-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |